CRISIL Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹32,025 Cr
- Book Value
- ₹447
- Stock P/E
- 36.2
- Dividend Yield
- 0.57%
- ROE
- 24.5%
- ROCE
- 32.6%
- PEG Ratio
- 2.51
- EV/EBITDA
- 23.7
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·CRISIL Ltd closed at ₹4,499.40 on 19 August 2026, up 1.3% on the day, 6.0% above its 50-day average, 17.5% below its 52-week high, with volume at 1.02× its 20-session average.
- RSI 14
- 56.9
- vs 50-day SMA
- +6.0%
- vs 200-day SMA
- +4.2%
- From 52-week high
- -17.5%
- Relative volume
- 1.02×
- 20-day return
- +0.1%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
CRISIL share price today
CRISIL (NSE: CRISIL) is two annuities under one S&P-controlled roof. The first: India’s premier credit-rating franchise — the name treasurers ask for first in a regulated oligopoly where demand is written into law. The second, larger by revenue: global research and analytics — risk models, benchmarking and research delivered to international banks and buy-side firms from Indian cost bases, an offshore annuity the rating multiple tends to obscure.
The blend produces 32.6% ROCE, 29.8% operating margins, and the steadiest earnings stream in its peer group. At 36.2×, the tension is how much earnings acceleration remains when both the ratings and analytics annuities already command a premium.
Ratings prestige, analytics scale
In ratings, CRISIL’s brand premium wins the marquee mandates and prices above the field — reputation is the product, and S&P parentage compounds it. In analytics, the Global Research & Risk Solutions arm rides two structural flows: financial-institution cost pressure (offshoring model risk and research) and regulatory complexity (every new capital rule is billable work). Neither business needs capital; both throw off cash.
Watch-items: bond-issuance cycles for the ratings arm, global banking cost cycles for analytics (bank belt-tightening cuts research budgets too), S&P’s related-party pricing, and the rupee (analytics revenue is substantially dollar-linked).
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹32,025 Cr |
| P/E (TTM) | 36.2 |
| EV/EBITDA | 23.7 |
| Operating margin | 29.8% |
| ROE / ROCE | 24.5% / 32.6% |
| Debt to equity | 0.10 |
| Sales CAGR (5y) | 13.0% |
| Profit CAGR (5y) | 14.4% |
| Promoter holding | 66.6% (S&P Global) |
| EPS (TTM) | ₹120.3 |
CRISIL share price target 2026 to 2030
EPS base ₹120.3 (TTM). Bear: issuance softens and bank research budgets shrink — 8% growth, multiple at 24×. Base: both annuities compound low-teens — 13% growth at 31×. Bull: bond-market deepening plus analytics wins — 17% growth at 40×.
From ₹4,357, the base case is ≈ +58% over four and a half years plus dividends; the bear is −3%. Downside this shallow is what dual annuities buy — the range below simply insists on paying annuity prices for them.
Reasons to own CRISIL (at the right price)
- The premium seat in a regulated ratings oligopoly — reputation prices above the field.
- Global analytics is a second annuity most rating-stock analyses undercount.
- S&P parentage: governance, technology and referral flow.
- 33% ROCE with negligible capital needs — cash compounds or returns.
- Dollar-linked analytics revenue hedges the domestic cycle.
The risks: global bank cost-cutting hits analytics first, ratings reputation is one scandal from damage, and a 66.6% parent sets strategy minorities ride along with.
What to weigh at the current price
CRISIL offers two quality annuities, but 36.2× is fair only if ratings and global analytics continue compounding together.
FAQ
What is the CRISIL share price target for 2030? The table above sets out bear, base and bull scenarios for each year through 2030. These are valuation sensitivities, not promised prices.
What is CRISIL’s analytics business? Global Research & Risk Solutions — outsourced research, risk modelling and benchmarking for international banks and asset managers, delivered from India. It is the larger revenue segment.
Why does CRISIL trade richer than CARE Ratings? Brand premium in ratings, the global analytics annuity, and S&P parentage — quality layers CARE doesn’t carry, priced accordingly.
When are CRISIL’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.